Cost-effectiveness of Spironolactone for Adult Female Acne (SAFA): economic evaluation alongside a randomised controlled trial

Conclusions
The results demonstrate a high level of uncertainty, particularly with respect to estimates of incremental QALYs. Compared with no active systemic treatment, spironolactone was estimated to be marginally cost-effective where multiple imputation was performed but was not cost-effective in complete case analysis.

Trial registration number
ISRCTN registry (ISRCTN12892056).

Source: BMJ Open - December 11, 2023 Category: General Medicine Authors: Pyne, S., Sach, T. H., Lawrence, M., Renz, S., Eminton, Z., Stuart, B., Thomas, K. S., Francis, N., Soulsby, I., Thomas, K., Permyakova, N. V., Ridd, M. J., Little, P., Muller, I., Nuttall, J., Griffiths, G., Layton, A. M., Santer, M. Tags: Open access, Health economics Source Type: research